Details

Autor(en) / Beteiligte

• Cappellini, M. Domenica
• Viprakasit, Vip
• Taher, Ali T
• Georgiev, Pencho
• Kuo, Kevin H.M
• Coates, Thomas
• Voskaridou, Ersi
• Liew, Hong-Keng
• Pazgal-Kobrowski, Idit
• Forni, G.L
• Perrotta, Silverio
• Khelif, Abderrahim
• Lal, Ashutosh
• Kattamis, Antonis
• Vlachaki, Efthymia
• Origa, Raffaella
• Aydinok, Yesim
• Bejaoui, Mohamed
• Ho, P. Joy
• Chew, Lee-Ping
• Bee, Ping-Chong
• Lim, Soo-Min
• Lu, Meng-Yao
• Tantiworawit, Adisak
• Ganeva, Penka
• Gercheva, Liana
• Shah, Farrukh
• Neufeld, Ellis J
• Thompson, Alexis
• Laadem, Abderrahmane
• Shetty, Jeevan K
• Zou, Jun
• Zhang, Jennie
• Miteva, Dimana
• Zinger, Tatiana
• Linde, Peter G
• Sherman, Matthew L
• Hermine, Olivier
• Porter, John
• Piga, Antonio

Titel

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia

Ist Teil von

• The New England journal of medicine, 2020-03, Vol.382 (13), p.1219-1231

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Patients with transfusion-dependent β-thalassemia were randomly assigned to receive luspatercept (a binder for TGF-β family member ligands) or placebo. During any 12-week period, a greater percentage of patients in the luspatercept group than in the placebo group had a reduction of at least 33% (70.5% vs. 29.5%) or at least 50% (40.2% vs. 6.3%) in the transfusion requirement.